are sensed by the sterol regulatory-element binding proteins (Srebp); the upstream regulator analysis indicates that Srebp and insulin signaling (which can also control expression of genes for cholesterol synthesis, uptake and transport) appear to be reduced. Decreases in brain cholesterol can have deleterious effects. Lovastatin applied to primary hippocampus neurons, leading to decreases in cholesterol, impaired synaptic vesicle release and decreased neurite growth (Mailman et al., 2011).
